These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

RedHill Biopharma Ltd (RDHL) reported its Q1 2022 earnings, revealing a decrease in net revenues to $18.2 million from $22.1 million in the previous quarter. Despite this, the company achieved a gross ...

Swiss biotech Bioversys AG shares started trading at 36.5 Swiss francs ($40.29) on the SIX Swiss Exchange on Friday, slightly up from the final price for its initial public offering (IPO) of 36 Swiss ...

Ma Songjiang, President of Gyre Therapeutics, Inc. (NASDAQ:GYRE), a $1.1 billion market cap biotech company with a robust ...

The genomics industry is set for growth due to advancements in personalized medicine, diagnostics, and biotech innovations.

AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...

Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

RenovoRx's innovative RenovoCath and TAMP platform show promising clinical data. Click here to read why RNXT stock presents ...

The recent volatility in our stock appears to be driven by misconceptions and a lack of understanding about our business and long-term strategy, but I want to reassure our investors that there have ...

Leerink Partnrs lowered their Q1 2025 earnings per share (EPS) estimates for Ironwood Pharmaceuticals in a research report issued on Wednesday, January 29th. Leerink Partnrs analyst F. Khurshid now ...